Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

David Mischoulon, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by David Mischoulon and Marlene Freeman.
Connection Strength

2.884
  1. Mischoulon D, Freeman MP. Omega-3 fatty acids in psychiatry. Psychiatr Clin North Am. 2013 Mar; 36(1):15-23.
    View in: PubMed
    Score: 0.589
  2. Freeman MP, Fava M, Lake J, Trivedi MH, Wisner KL, Mischoulon D. Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. J Clin Psychiatry. 2010 Jun; 71(6):669-81.
    View in: PubMed
    Score: 0.487
  3. Freeman MP, Pooley J, Flynn MJ, Baer L, Mischoulon D, Mou D, Fava M. Guarding the Gate: Remote Structured Assessments to Enhance Enrollment Precision in Depression Trials. J Clin Psychopharmacol. 2017 Apr; 37(2):176-181.
    View in: PubMed
    Score: 0.195
  4. Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Mol Psychiatry. 2016 10; 21(10):1483-4.
    View in: PubMed
    Score: 0.187
  5. Mischoulon D, Zajecka J, Freeman MP, Fava M. Does folic acid interfere with lamotrigine? Lancet Psychiatry. 2016 08; 3(8):704-705.
    View in: PubMed
    Score: 0.187
  6. Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Mol Psychiatry. 2016 10; 21(10):1372-80.
    View in: PubMed
    Score: 0.178
  7. Nyer M, Doorley J, Durham K, Yeung AS, Freeman MP, Mischoulon D. What is the role of alternative treatments in late-life depression? Psychiatr Clin North Am. 2013 Dec; 36(4):577-96.
    View in: PubMed
    Score: 0.154
  8. Desseilles M, Witte J, Chang TE, Iovieno N, Dording C, Ashih H, Nyer M, Freeman MP, Fava M, Mischoulon D. Massachusetts General Hospital SAFER criteria for clinical trials and research. Harv Rev Psychiatry. 2013 Sep-Oct; 21(5):269-74.
    View in: PubMed
    Score: 0.152
  9. Desseilles M, Witte J, Chang TE, Iovieno N, Dording CM, Ashih H, Nyer M, Freeman MP, Fava M, Mischoulon D. Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant treatment response questionnaire. J Clin Psychiatry. 2011 Aug; 72(8):1152-4.
    View in: PubMed
    Score: 0.132
  10. Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry. 2010 Jun; 71(6):682-8.
    View in: PubMed
    Score: 0.122
  11. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE, Marangell LB, Richardson AJ, Lake J, Stoll AL. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006 Dec; 67(12):1954-67.
    View in: PubMed
    Score: 0.095
  12. Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K, Freeman MP, Maes M, Matsuoka YJ, Belmaker RH, Marx W, Pariante C, Berk M, Jacka F, Su KP. Corrigendum to "A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder". [J Affect Disord. 15 (2020) 233-238]. J Affect Disord. 2020 Sep 01; 274:1226-1227.
    View in: PubMed
    Score: 0.061
  13. Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K, Freeman MP, Maes M, Matsuoka YJ, Belmaker RH, Marx W, Pariante C, Berk M, Jacka F, Su KP. A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder. J Affect Disord. 2020 Mar 15; 265:233-238.
    View in: PubMed
    Score: 0.059
  14. Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K, Freeman MP, Maes M, Matsuoka YJ, Belmaker RH, Jacka F, Pariante C, Berk M, Marx W, Su KP. International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder. Psychother Psychosom. 2019; 88(5):263-273.
    View in: PubMed
    Score: 0.058
  15. Kinrys G, Gold AK, Pisano VD, Freeman MP, Papakostas GI, Mischoulon D, Nierenberg AA, Fava M. Tachyphylaxis in major depressive disorder: A review of the current state of research. J Affect Disord. 2019 02 15; 245:488-497.
    View in: PubMed
    Score: 0.054
  16. Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, Papakostas GI. Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimul. 2018 Jan - Feb; 11(1):75-84.
    View in: PubMed
    Score: 0.051
  17. Sarris J, Logan AC, Akbaraly TN, Paul Amminger G, Balanzá-Martínez V, Freeman MP, Hibbeln J, Matsuoka Y, Mischoulon D, Mizoue T, Nanri A, Nishi D, Parletta N, Ramsey D, Rucklidge JJ, Sanchez-Villegas A, Scholey A, Su KP, Jacka FN. International Society for Nutritional Psychiatry Research consensus position statement: nutritional medicine in modern psychiatry. World Psychiatry. 2015 Oct; 14(3):370-1.
    View in: PubMed
    Score: 0.044
  18. Sarris J, Logan AC, Akbaraly TN, Amminger GP, Balanzá-Martínez V, Freeman MP, Hibbeln J, Matsuoka Y, Mischoulon D, Mizoue T, Nanri A, Nishi D, Ramsey D, Rucklidge JJ, Sanchez-Villegas A, Scholey A, Su KP, Jacka FN. Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry. 2015 Mar; 2(3):271-4.
    View in: PubMed
    Score: 0.042
  19. Lin PY, Mischoulon D, Freeman MP, Matsuoka Y, Hibbeln J, Belmaker RH, Su KP. Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol Psychiatry. 2012 Dec; 17(12):1161-3; author reply 1163-7.
    View in: PubMed
    Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.